查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990377

個人化醫療市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Personalized Medicine Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，個人化醫療市場價值將達到 4,668.4 億美元，到 2026 年將成長至 5,127.3 億美元，到 2032 年將達到 9,239.4 億美元，複合年成長率為 10.24%。

主要市場統計數據
基準年 2025 4668.4億美元
預計年份：2026年 5127.3億美元
預測年份：2032年 9239.4億美元
複合年成長率 (%) 10.24%

個人化醫療的創新正在重新定義患者照護，並塑造下一代標靶治療。

近年來，個人化醫療已成為醫療創新領域的前沿，它利用基因組分析和精準診斷的洞見，為每位患者量身定做治療方案。分子生物學的突破性進展使研究人員能夠揭示疾病的遺傳基礎，從而為靶向特定生物標記的治療方法鋪平了道路。高通量定序和生物資訊學平台的進步加速了這項從傳統、統一的治療方法向個人化介入的轉變，這些平台以前所未有的方式揭示了疾病發病機制背後的分子因素。因此，臨床醫生可以識別出最能從特定治療方法中獲益的患者，從而提高療效並最大限度地減少副作用。數位健康工具的整合進一步拓展了這一潛力，實現了對患者反應的持續監測和適應性治療方案的發展。

基因組定序和數位健康平台的快速發展正在改變全球個人化醫療的格局。

過去十年，在基因組定序、數位健康整合和人工智慧分析等技術突破的推動下，個人化醫療領域經歷了變革性的變化。自從全基因組定序技術問世以來，其成本已大幅下降，從而揭示了以往難以獲取的患者特異性突變譜信息，並使伴隨診斷在臨床實踐中得以常規應用。同時，數位健康平台和穿戴式裝置的普及使得生物標記的遠端監測成為可能，讓醫療專業人員能夠近乎即時地了解治療反應和疾病進展。此外，監管機構也推出了適應性框架，以加快標靶治療的核准，尤其是在腫瘤和罕見疾病領域，這反映了其對以患者為中心的醫療路徑的更廣泛承諾。

美國預計將於 2025 年加強關稅力度，這將重塑全球個人化醫療市場的供應鏈和成本結構。

美國近期針對2025年關稅調整的政策決定，為個人化醫療的價值鏈帶來了新的複雜性。對高品質試劑、定序設備和專用實驗室耗材等關鍵組件徵收的關稅，可能會增加投入成本，並擾亂現有的籌資策略。依賴跨境供應鏈的企業必須應對成本波動帶來的利潤空間壓縮和策略調整。為此，許多產業相關人員正著手實現供應商多元化、探索替代製造地，並將關鍵生產流程在地化，以降低關稅變化帶來的風險。

從產品類型、技術、應用和最終用戶等方面進行多樣化細分，揭示了個人化醫療領域中蘊藏的微妙機會。

對市場區隔的詳細分析揭示了產品類型、技術、應用和最終用戶類別之間截然不同的動態，這些因素共同構成了個人化醫療的生態系統。從產品類型來看，診斷方式包括伴隨診斷、基因檢測、影像學和分子診斷，每種方式在識別生物標記和對患者群體進行分層方面都發揮著至關重要的作用。另一方面，治療方案包括細胞和基因療法、免疫療法、單株抗體和傳統藥物，反映了針對疾病潛在機制的多種治療方法。這種二分法凸顯了診斷和治療創新之間的互補性，其中準確的疾病特徵描述對於制定標靶干預策略至關重要。

美洲、歐洲、中東和非洲以及亞太地區的不同區域趨勢正在以各種方式推動個人化醫療的普及。

個人化醫療的區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區不同的優先事項和發展軌跡。在美洲，對研究基礎設施的大力投資以及主要企業的生物製藥和診斷公司的存在，正在推動基因組檢測和標靶治療的快速普及。以價值為導向的舉措和舉措，以及健全的臨床實驗室網路和報銷管道，正在進一步加速市場擴張和新型療法的臨床應用。

領先的創新者和策略夥伴關係正在加速個人化醫療生態系統的突破和競爭優勢。

個人化醫療領域的主要企業正透過對研發的策略性投資以及加速治療方法創新的合作來脫穎而出。一些生物醫學公司已與基因組學技術供應商建立獨家合作關係，共同開發下一代定序技術；其他公司則投資於專有的生物資訊平台，以增強對分子數據的解讀能力。這些策略舉措不僅增強了企業的內部能力，也有助於它們在競爭激烈的市場環境中建立差異化優勢。

透過前瞻性策略和戰術性投資，產業領導者可以利用新興的個人化醫療趨勢，克服監管障礙。

為了充分利用個人化醫療的發展勢頭，並應對不斷變化的監管和商業環境，產業領導者應考慮以下幾項前瞻性策略。首先，投資模組化和靈活的製造能力將增強企業應對供應鏈中斷和關稅導致的成本波動的能力。透過建立關鍵部件的本地生產基地，企業既能確保供應的連續性，又能遵守區域貿易法規。同時，促進研發、監管事務和商業部門之間的跨學科合作，將能有效地將科學發現轉化為可上市的解決方案，從而最大限度地縮短患者獲益的時間。

嚴謹的資料收集、分析和檢驗調查方法，為個人化醫療市場提供全面的研究途徑。

為確保準確性和可靠性，本分析所依據的研究採用了嚴謹的多階段方法。首先，進行了二次調查，涵蓋了廣泛可獲得的資訊來源，例如同行評審期刊、監管出版刊物和行業白皮書，以建立對技術趨勢和市場動態的基本理解。在此階段，也查閱了專利資料庫和臨床實驗室註冊信息，以識別個人化醫療領域的關鍵創新和開發平臺。

整合式、個人化醫療創新和策略調整可望推動全球永續成長，並改變醫療服務模式。

隨著個人化醫療從概念框架走向臨床實踐，精準診斷、標靶治療和數位健康平台的整合有望徹底改變全球患者的治療效果。技術創新、策略性產業合作和適應性監管流程的整合，為更有效率的醫療服務奠定了基礎。然而，供應鏈波動、關稅影響以及區域應用差異等挑戰，仍是相關人員在尋求最大限度發揮個人化醫療潛力時需要考慮的重要因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 個人化醫療市場：依產品類型分類

  • 診斷
    • 伴隨診斷
    • 基因檢測
    • 影像
    • 分子診斷
  • 治療
    • 細胞和基因治療
    • 免疫療法
    • 單株抗體
    • 製藥

第9章：個人化醫療市場：依技術分類

  • 生物資訊學
  • 月刊健康與人工智慧
  • 基因組學和蛋白​​質組學
  • 藥物基因體學

第10章：個人化醫療市場：依應用領域分類

  • 循環系統
    • 心律不整
    • 心臟衰竭
  • 內分泌學
  • 感染疾病
    • 細菌
    • 病毒性的
  • 神經病學
    • 神經退化性疾病
    • 精神病學
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

第11章：個人化醫療市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢測實驗室
  • 醫院和診所

第12章 個人化醫療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：個人化醫療市場：按群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 個人化醫療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國個人化醫療市場

第16章：中國的個人化醫療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AMGEN INC
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc
  • Bio-Techne Corporation
  • bluebird bio, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Exact Sciences Corporation
  • GE Healthcare Technologies, Inc
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc
  • PierianDx, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4D00F1312F65

The Personalized Medicine Market was valued at USD 466.84 billion in 2025 and is projected to grow to USD 512.73 billion in 2026, with a CAGR of 10.24%, reaching USD 923.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 466.84 billion
Estimated Year [2026] USD 512.73 billion
Forecast Year [2032] USD 923.94 billion
CAGR (%) 10.24%

Innovations in Personalized Medicine Are Redefining Patient Care and Shaping the Next Generation of Targeted Therapeutics

In recent years, personalized medicine has emerged at the forefront of healthcare innovation, harnessing genomic insights and precision diagnostics to tailor treatments to individual patient profiles. Breakthroughs in molecular biology have enabled researchers to decode the genetic underpinnings of disease, paving the way for therapies that target specific biomarkers. This shift from traditional one-size-fits-all approaches to personalized interventions has been catalyzed by advancements in high-throughput sequencing and bioinformatics platforms, which deliver unprecedented resolution into the molecular drivers of pathology. As a result, clinicians can now identify patients who will benefit most from a given therapy, thereby improving efficacy rates and minimizing adverse effects. The integration of digital health tools further amplifies this potential, allowing for continuous monitoring of patient responses and adaptive treatment regimens.

Moreover, the convergence of data analytics and artificial intelligence has accelerated decision-making processes, enabling dynamic patient stratification and real-time adjustments to therapeutic protocols. Through collaborative efforts between research institutions, technology providers, and clinical stakeholders, personalized medicine is transitioning from theoretical promise to clinical reality. This introduction lays the groundwork for a comprehensive exploration of the key drivers, challenges, and emerging trends that define the evolving landscape of individualized healthcare solutions.

Rapid Advances in Genomic Sequencing and Digital Health Platforms Are Transforming the Personalized Medicine Landscape Globally

Over the past decade, the personalized medicine landscape has undergone transformative shifts driven by technological breakthroughs in genomic sequencing, digital health integration, and AI-driven analytics. The cost of whole-genome sequencing has plummeted dramatically since its inception, unlocking previously inaccessible insights into patient-specific mutation profiles and enabling the routine application of companion diagnostics in clinical practice. At the same time, the proliferation of digital health platforms and wearable devices has facilitated remote monitoring of biomarkers, empowering healthcare providers to detect treatment responses and disease progression in near real-time. In parallel, regulatory agencies have introduced adaptive frameworks that accelerate the approval of targeted therapies, particularly in oncology and rare disease domains, reflecting a broader commitment to patient-centric care pathways.

These developments have been complemented by strategic partnerships between biopharmaceutical companies and technology firms, fostering an ecosystem that leverages cross-disciplinary expertise to address complex therapeutic challenges. Collaborative research consortia now convene to standardize genomic data protocols and validate digital health endpoints, further solidifying the infrastructure needed for scalable implementation. In this context, value-based care models are increasingly being adopted, aligning reimbursement with treatment outcomes rather than volumetric service delivery. As personalized medicine continues to mature, these converging forces of innovation, policy evolution, and collaborative synergy are reshaping the healthcare paradigm, setting the stage for unprecedented levels of precision, efficiency, and patient empowerment.

Escalating United States Tariff Policies in 2025 Are Reshaping Supply Chains and Cost Structures in Personalized Medicine Markets Worldwide

Recent policy decisions regarding tariff adjustments in the United States for the year 2025 have introduced a new layer of complexity to the personalized medicine value chain. Tariffs applied to critical components such as high-grade reagents, sequencing equipment, and specialized laboratory consumables have the potential to increase input costs and disrupt established procurement strategies. Companies reliant on cross-border supply networks must now navigate a landscape where cost variances can erode profit margins and necessitate strategic recalibrations. In response, several industry players have begun diversifying their supplier base, seeking alternative manufacturing locations and localizing key production processes to mitigate exposure to tariff volatility.

Beyond direct cost implications, the tariff regime has also influenced collaborative research agreements, as international partners reassess the economic feasibility of joint ventures and technology transfers. Institutions in North America are exploring co-development frameworks with partners in tariff-exempt regions, optimizing for intellectual property protection and tax incentives. Simultaneously, small and medium-sized enterprises face heightened barriers to entry due to increased capital requirements and the need for more robust logistical planning. Despite these challenges, proactive stakeholder engagement with policy-makers and trade associations has emerged as a critical mechanism for advocating for tariff exemptions on life-saving and research-intensive products. Overall, the evolving tariff environment underscores the importance of agile supply chain strategies and cross-sector collaboration in sustaining the momentum of personalized medicine innovation.

Diverse Segmentation Across Product Types Technologies Applications and End Users Reveals Nuanced Opportunities in Personalized Medicine

An in-depth examination of market segmentation reveals distinct dynamics across product type, technology, application, and end user categories that collectively shape the personalized medicine ecosystem. Examining product type, diagnostics modalities span companion diagnostics, genetic testing, imaging diagnostics, and molecular diagnostics, each playing a pivotal role in identifying biomarkers and stratifying patient populations. Therapeutic solutions, on the other hand, encompass cell and gene therapy, immunotherapy, monoclonal antibodies, and conventional pharmaceuticals, reflecting a broad spectrum of approaches to target underlying disease mechanisms. This bifurcation underscores the complementary nature of diagnostic and therapeutic innovation, whereby precise disease characterization informs targeted intervention strategies.

When viewed through the lens of technology platforms, bioinformatics, digital health and artificial intelligence, genomics and proteomics, as well as pharmacogenomics emerge as critical enablers. Bioinformatics tools drive data interpretation, while digital health applications and AI algorithms facilitate real-time patient monitoring and adaptive treatment algorithms. Genomics and proteomics provide the molecular framework for identifying therapeutic targets, and pharmacogenomics informs drug selection based on individual metabolic profiles. These technologies function in concert to enhance the predictive power and personalized precision of clinical decision making.

Application areas further delineate the market's complexity. Cardiology divisions focus on arrhythmia and heart failure, endocrinology leverages hormone profiling, and infectious disease strategies address both bacterial and viral challenges. Neurology initiatives target neurodegenerative disorders and psychiatric conditions, while oncology efforts span hematologic malignancies and solid tumors. Finally, end user ecosystems include academic and research institutes, diagnostic laboratories, and hospitals and clinics, each serving as a crucial node in the translational continuum from discovery science to patient care. This multifaceted segmentation framework highlights the nuanced opportunities and challenges that stakeholders must navigate to drive personalized medicine forward.

Distinct Regional Dynamics Across Americas Europe Middle East Africa and Asia Pacific Are Driving Personalized Medicine Adoption Differently

Regional trends in personalized medicine reflect divergent priorities and developmental trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong investment in research infrastructure and the presence of leading biopharmaceutical and diagnostic companies drive rapid adoption of genomic testing and targeted therapies. Policy initiatives that emphasize value-based care, alongside a robust network of clinical trial sites and reimbursement pathways, further accelerate market expansion and clinical translation of novel therapies.

In contrast, the Europe Middle East and Africa region exhibits a heterogeneous landscape. Western Europe benefits from comprehensive healthcare coverage and regulatory harmonization through centralized agencies, fostering an environment conducive to the uptake of precision diagnostics and innovative treatment modalities. Conversely, emerging markets within the Middle East and Africa are characterized by nascent healthcare infrastructures and reliance on donor-funded programs, which presents both challenges and opportunities for scalable implementation of personalized medicine solutions.

Meanwhile, the Asia-Pacific region stands out for its large patient populations and growing focus on domestic manufacturing capabilities. Governments in key markets are investing in national genomic sequencing initiatives, and collaborative networks have been established to standardize data protocols and facilitate cross-border research. Additionally, partnerships between multinational corporations and local enterprises are enabling technology transfer and capacity building, positioning the region as a critical hub for future personalized medicine developments.

Leading Innovators and Strategic Collaborations Are Accelerating Breakthroughs and Competitive Positioning in the Personalized Medicine Ecosystem

Leading organizations in the personalized medicine arena are distinguishing themselves through strategic investment in research and development, as well as through collaborative alliances that accelerate therapeutic innovation. Several biomedical firms have secured exclusive partnerships with genomic technology providers to co-develop next-generation sequencing assays, while others have invested in proprietary bioinformatics platforms that enhance molecular data interpretation. These strategic maneuvers not only bolster internal capabilities but also create differentiated positioning in a highly competitive landscape.

Moreover, cross-sector collaborations are gaining momentum, with pharmaceutical companies partnering with digital health startups to integrate real-time patient monitoring into clinical trial designs. Such alliances enable more responsive trial protocols, reduce time to actionable insights, and improve patient retention rates. At the same time, emerging biotech companies are pursuing targeted acquisitions to expand their pipeline portfolios and gain access to novel therapeutic platforms, particularly in high-growth areas like cell and gene therapy. Meanwhile, diagnostic firms are forming consortia with academic institutions and contract research organizations to validate biomarkers and regulatory endpoints, reinforcing the evidentiary foundation required for market approval. By leveraging a combination of organic research efforts and external collaborations, these industry players are positioning themselves to lead the transition toward truly personalized healthcare solutions.

Proactive Strategies and Tactical Investments Will Empower Industry Leaders to Capitalize on Emerging Personalized Medicine Trends and Overcome Regulatory Hurdles

To capitalize on the momentum of personalized medicine and navigate the evolving regulatory and commercial landscape, industry leaders should consider several proactive strategies. First, investing in modular and flexible manufacturing capabilities will enhance resilience against supply chain disruptions and tariff-induced cost fluctuations. By adopting localized production hubs for critical components, organizations can ensure continuity of supply while maintaining compliance with regional trade regulations. Concurrently, fostering cross-disciplinary collaboration between R&D, regulatory affairs, and commercial teams will streamline the translation of scientific discoveries into market-ready solutions, minimizing time to patient benefit.

Second, integrating advanced data analytics and artificial intelligence into clinical development and patient engagement workflows will unlock new efficiencies. Machine learning models can predict patient responses and optimize trial design, while digital health platforms facilitate remote monitoring and adherence tracking. These technological investments will not only improve clinical outcomes but also generate real-world evidence that supports value-based reimbursement models.

Third, expanding strategic partnerships with academic centers, specialized contract research organizations, and technology providers will enhance access to cutting-edge expertise and infrastructure. Establishing co-development agreements and consortium-based research programs can spread risk and accelerate proof-of-concept validation. Additionally, engaging with policy-makers and industry associations to advocate for tariff exemptions on essential diagnostic and therapeutic components will help mitigate cost pressures.

Finally, prioritizing patient-centric frameworks-such as incorporating patient-reported outcomes and personalized engagement strategies-will strengthen adoption and long-term market success. By aligning commercialization strategies with patient needs and payer expectations, organizations can build sustainable value propositions that endure in a rapidly shifting healthcare environment.

Rigorous Data Collection Analysis and Validation Methodologies Underpinning the Comprehensive Research Approach in Personalized Medicine Markets

The research underpinning this analysis employs a rigorous multi-stage approach to ensure accuracy and reliability. Initially, secondary research was conducted across a broad spectrum of publicly available sources, including peer-reviewed journals, regulatory agency publications, and industry white papers, to establish a foundational understanding of technological trends and market dynamics. This phase also involved the review of patent databases and clinical trial registries to identify key innovations and developmental pipelines in personalized medicine.

Following this, primary research was executed through structured interviews with subject matter experts, including clinicians, technology providers, and regulatory consultants. These interviews offered qualitative insights into evolving adoption patterns, reimbursement challenges, and strategic priorities. Cross-functional dialogues with industry executives provided additional perspective on investment drivers and partnership opportunities.

Data triangulation techniques were then applied to reconcile findings from both primary and secondary sources. Quantitative data points were validated through multiple independent channels to strengthen confidence in the insights presented. Finally, an iterative validation process was conducted, where preliminary conclusions were reviewed by an external advisory panel to ensure objectivity and relevance. This comprehensive methodology ensures that the analysis reflects the latest evidence and expert perspectives, providing a robust foundation for strategic decision-making in the personalized medicine arena.

Integrated Personalized Medicine Innovations and Strategic Adaptations Are Poised to Drive Sustainable Growth and Transform Healthcare Delivery Models Worldwide

As personalized medicine advances from conceptual frameworks to clinical reality, the integration of precision diagnostics, targeted therapeutics, and digital health platforms is poised to transform patient outcomes globally. The convergence of technological innovation, strategic industry collaborations, and adaptive regulatory pathways has laid the groundwork for more effective and efficient care delivery. However, challenges such as supply chain volatility, tariff impacts, and heterogeneous regional adoption remain critical considerations for stakeholders seeking to maximize the potential of personalized interventions.

By embracing agile manufacturing strategies, fostering co-development partnerships, and leveraging advanced data analytics, organizations can navigate these complexities and achieve competitive differentiation. Simultaneously, prioritizing patient-centric approaches and cultivating evidence generation will bolster payer confidence and facilitate broader market access. As regional ecosystems continue to mature, opportunities for localized innovation and cross-border collaboration will further accelerate progress. Ultimately, the future of healthcare lies in the ability to tailor interventions to individual patient profiles, and those entities that successfully align scientific rigor with operational agility are best positioned to lead this transformative journey.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Personalized Medicine Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Companion Diagnostics
    • 8.1.2. Genetic Testing
    • 8.1.3. Imaging Diagnostics
    • 8.1.4. Molecular Diagnostics
  • 8.2. Therapeutics
    • 8.2.1. Cell & Gene Therapy
    • 8.2.2. Immunotherapy
    • 8.2.3. Monoclonal Antibodies
    • 8.2.4. Pharmaceuticals

9. Personalized Medicine Market, by Technology

  • 9.1. Bioinformatics
  • 9.2. Digital Health & AI
  • 9.3. Genomics & Proteomics
  • 9.4. Pharmacogenomics

10. Personalized Medicine Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Arrhythmia
    • 10.1.2. Heart Failure
  • 10.2. Endocrinology
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Neurology
    • 10.4.1. Neurodegenerative
    • 10.4.2. Psychiatric
  • 10.5. Oncology
    • 10.5.1. Hematologic Malignancies
    • 10.5.2. Solid Tumors

11. Personalized Medicine Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics

12. Personalized Medicine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Personalized Medicine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Personalized Medicine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Personalized Medicine Market

16. China Personalized Medicine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. AMGEN INC
  • 17.8. BGI Genomics Co., Ltd.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Biogen Inc
  • 17.11. Bio-Techne Corporation
  • 17.12. bluebird bio, Inc.
  • 17.13. CRISPR Therapeutics AG
  • 17.14. Danaher Corporation
  • 17.15. Exact Sciences Corporation
  • 17.16. GE Healthcare Technologies, Inc
  • 17.17. Guardant Health, Inc.
  • 17.18. Illumina, Inc.
  • 17.19. Myriad Genetics, Inc.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc
  • 17.22. PierianDx, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Roche Holding AG
  • 17.25. Siemens Healthcare GmbH
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERSONALIZED MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERSONALIZED MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)